A. V. Lokhova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
A. V. Lokhova has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandr Igorevich Khalimon
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
3 shared publications - Gulnara Faridovna Khamadeeva
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
3 shared publications - Malika Maratovna Khodzhibekova
P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre
3 shared publications - Andrei Dmitrievich Kaprin
RUDN University
2 shared publications - Daria Yurevna Khodakova
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
2 shared publications - Irina Valentinovna Pylova
Department of Nuclear Medicine, Moscow Oncology Research Institute, FSBI "National Medical Research Radiological Centre" of the Ministry of Health of the Russian Federation, Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Elsevier in The EANM Journal
- Vol. 4
Which SUV is more stable for PSMA-positivity thresholding? EARL harmonized lesional SUV versus reference tissue SUV
- 21 May 2026
- Published by Elsevier in The EANM Journal
- Vol. 4
Open AccessWhich SUV is more stable for PSMA-positivity thresholding? EARL harmonized lesional SUV versus reference tissue SUV
- Open Access
- 16 June 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (2) , 46-59
Value of [18F]FDG PET/CT for predicting epidermal growth factor receptor gene mutation status in patients with newly diagnosed non-small cell lung cancer: a retrospective single center study
Purpose of the study. The aim of this study was to evaluate the role of [18F]FDG PET/CT for predicting epidermal growth factor receptor (EGFR) gene mutation status in patients with newly diagnosed non-small cell lung cancer (NSCLC).Patients and methods. This retrospective single center study included 63 patients with NSCLC who underwent [18F]FDG PET/ CT and were divided into the mutant (n = 30) and wild-type groups (n = 33) based on EGFR mutation status. Maximal diameter (Dmax) and anatomical volume of each primary tumor lesion were measured, [18F]FDG uptake was analyzed by measurement of SUVmax, SUVpeak, MTV, TLG and TLR. TLG was measured using PET segmentation method by 3D-Isocontour tool with 41 % of SUVmax threshold (TLG41 %) and threshold adapted to the anatomical volume (TLGCT). Acquisition data of NEMA IEC Body Phantom Set NU2–2018 was applied for plotting the recovery coefficients curves that used for following partial volume effect correction (without correction – PVE, after correction – cPVE).Results. Medians of lesions’ metrics in the mutant and wild-type groups were, respectively: Dmax – 3 [2.5; 4] and 3.6 [2.5; 4.4] cm, p > 0.05; anatomical volume – 7 [5.2; 14.7] and 12.1 [4.6; 24.4] ml, p > 0.05; PVE SUVmax – 6.6 [3.6; 9.3] and 8.5 [6.4; 10], p > 0.05; cPVE SUVmax – 5.7 [3.2; 7.6] and 6.8 [5.4; 8.1], p > 0.05; PVE SUVpeak – 5.7 [2.8; 7.6] and 6.6 [5.2; 8.8], p > 0.05; cPVE SUVpeak – 5.2 [3; 6.8] and 6.7 [4.7; 7.7], p > 0.05; PVE MTV41 % – 5.4 [3.3; 10.4] and 9 [3.6; 16.2], p > 0.05; cPVE MTV41 % – 5.2 [3.3; 10.1] and 6.2 [3.6; 11.7], p > 0.05; PVE TLG41 % – 21.5 [9.2; 37.8] and 36.9 [10.2; 78], p > 0.05; cPVE TLG41 % – 28.9 [16; 46.4] and 24.9 [12.9; 66.4], p > 0.05; PVE TLGCT – 27.8 [11.5; 52.1] and 54.7 [14.4; 123], p > 0.05; cPVE TLGCT – 31 [14.7; 51.7] and 35.8 [16.2; 82.6], p > 0.05; PVE TLR – 3 [2; 5.2] and 4 [3; 5.3], p > 0.05; cPVE TLR – 3 [2.1; 4.5] and 3.6 [2.7; 5], p > 0.05.Conclusion. Our results suggest that [18F]FDG PET/CT has no significant value for predicting the EGFR gene mutation status in patients with newly diagnosed NSCLC.
- 16 June 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (2) , 46-59
Open AccessValue of [18F]FDG PET/CT for predicting epidermal growth factor receptor gene mutation status in patients with newly diagnosed non-small cell lung cancer: a retrospective single center study
Purpose of the study. The aim of this study was to evaluate the role of [18F]FDG PET/CT for predicting epidermal growth factor receptor (EGFR) gene mutation status in patients with newly diagnosed non-small cell lung cancer (NSCLC).Patients and methods. This retrospective single center study included 63 patients with NSCLC who underwent [18F]FDG PET/ CT and were divided into the mutant (n = 30) and wild-type groups (n = 33) based on EGFR mutation status. Maximal diameter (Dmax) and anatomical volume of each primary tumor lesion were measured, [18F]FDG uptake was analyzed by measurement of SUVmax, SUVpeak, MTV, TLG and TLR. TLG was measured using PET segmentation method by 3D-Isocontour tool with 41 % of SUVmax threshold (TLG41 %) and threshold adapted to the anatomical volume (TLGCT). Acquisition data of NEMA IEC Body Phantom Set NU2–2018 was applied for plotting the recovery coefficients curves that used for following partial volume effect correction (without correction – PVE, after correction – cPVE).Results. Medians of lesions’ metrics in the mutant and wild-type groups were, respectively: Dmax – 3 [2.5; 4] and 3.6 [2.5; 4.4] cm, p > 0.05; anatomical volume – 7 [5.2; 14.7] and 12.1 [4.6; 24.4] ml, p > 0.05; PVE SUVmax – 6.6 [3.6; 9.3] and 8.5 [6.4; 10], p > 0.05; cPVE SUVmax – 5.7 [3.2; 7.6] and 6.8 [5.4; 8.1], p > 0.05; PVE SUVpeak – 5.7 [2.8; 7.6] and 6.6 [5.2; 8.8], p > 0.05; cPVE SUVpeak – 5.2 [3; 6.8] and 6.7 [4.7; 7.7], p > 0.05; PVE MTV41 % – 5.4 [3.3; 10.4] and 9 [3.6; 16.2], p > 0.05; cPVE MTV41 % – 5.2 [3.3; 10.1] and 6.2 [3.6; 11.7], p > 0.05; PVE TLG41 % – 21.5 [9.2; 37.8] and 36.9 [10.2; 78], p > 0.05; cPVE TLG41 % – 28.9 [16; 46.4] and 24.9 [12.9; 66.4], p > 0.05; PVE TLGCT – 27.8 [11.5; 52.1] and 54.7 [14.4; 123], p > 0.05; cPVE TLGCT – 31 [14.7; 51.7] and 35.8 [16.2; 82.6], p > 0.05; PVE TLR – 3 [2; 5.2] and 4 [3; 5.3], p > 0.05; cPVE TLR – 3 [2.1; 4.5] and 3.6 [2.7; 5], p > 0.05.Conclusion. Our results suggest that [18F]FDG PET/CT has no significant value for predicting the EGFR gene mutation status in patients with newly diagnosed NSCLC.
- Open Access
- 14 April 2023
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 14 (1) , 63-72
Comparative assessment of 18F-PSMA-1007 biodistribution at 60 and 120 minutes after administration by PET/CT in prostate cancer patients
Сравнительная оценка биораспределения 18F-ПСМА-1007 через 60 и 120 минут после внутривенного введения при ПЭТ/КТ у пациентов, обследованных по поводу рака предстательной железы
- 14 April 2023
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 14 (1) , 63-72
Open AccessComparative assessment of 18F-PSMA-1007 biodistribution at 60 and 120 minutes after administration by PET/CT in prostate cancer patients
Сравнительная оценка биораспределения 18F-ПСМА-1007 через 60 и 120 минут после внутривенного введения при ПЭТ/КТ у пациентов, обследованных по поводу рака предстательной железы